Everything below concerns Anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-03. Numbers and descriptions here follow the published literature rather than marketing material.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
=== Heating === Heating methods are often used to ensure that glass and other lab equipment are free of pyrogenic material. Heat is applied by baking in a dry heat oven that is designed specifically for the depyrogenation process. Although endotoxins are relatively thermally stable, sufficient heating (250 °C for 30 min) results in a 3-log reduction of endotoxin levels. Due to the high temperature levels, this method is also not suitable when purifying proteins.
Following the season, the club's annual report noted the need for a spearhead full-forward, stating: "It is very apparent that no team is complete without a spearhead and your committee has high hopes of rectifying that fault this coming season". The 1949 season marked the debut of John Coleman. In his first appearance against Hawthorn in Round 1, 1949, he kicked 12 goals, establishing a round one record that stood for forty-five years. Coleman maintained this form throughout the season, kicking exactly 100 goals to become the first player to kick 100 goals in a season since Richmond's Jack Titus in 1940, and the first to do so in a debut season. Essendon qualified for the finals in 4th place and went on to win the premiership.
Statistics from 1998 show that there were wide racial disparities in arrests, prosecutions, sentencing and deaths. African-American drug users made up for 35% of drug arrests, 55% of convictions, and 74% of people sent to prison for drug possession crimes. Nationwide African-Americans were sent to state prisons for drug offenses 13 times more often than other races, even though they supposedly constituted only 13% of regular drug users. Human Rights Watch's report, "Race and the Drug War" (2000), provided extensive documentation of racial disparities, citing statistics and case studies highlighting the unequal treatment of racial and ethnic groups by law enforcement agencies, particularly in drug arrests. According to the report, in the US in 1999, compared to non-minorities, African Americans were far more likely to be arrested for drug crimes, and received much stiffer penalties and sentences. Reporting on the effects of state initiatives, the Department of Justice found that, from 1990 through 2000, "the increasing number of drug offenses accounted for 27% of the total growth among black inmates, 7% of the total growth among Hispanic inmates, and 15% of the growth among white inmates." In Malign Neglect – Race Crime and Punishment in America (1995), criminologist Michael Tonry wrote, "The War on Drugs foreseeably and unnecessarily blighted the lives of hundreds and thousands of young disadvantaged black Americans and undermined decades of effort to improve the life chances of members of the urban black underclass."
==== Medicare, Medicaid, and CHIP coverage ==== On 4 April 2025, the Trump administration declined to finalize a proposal from the Biden administration that would have required Medicare, Medicaid, and CHIP to broadly cover GLP-1s for weight loss. Despite the rejection, CMS has indicated that it might cover obesity medication in future rulemaking. But in November 2025, the Trump administration announced TrumpRx, an initiative similar to GoodRx to lower the price of GLP-1s to $245 per month for patients covered by Medicaid and CHIP and $50-month for Medicare patients if states opted in. Coverage for patients with obesity and at least one comorbidity like (elevated LDL-cholesterol, high blood pressure, or MASLD), will be implemented as early as 1 April 2026. The cost will be significantly higher to taxpayers since most health insurance companies do not cover it in their formulary. Before this change, most Medicaid and CHIP patients paid $3 a month, the same price as for brand-name medication. In December 2025, CMS announced the Medicare GLP-1 Bridge, a demonstration program running from 1 July to 31 December 2026, giving eligible Medicare Part D beneficiaries access to Wegovy and Zepbound at $50 per month. A longer-term program, the BALANCE Model, is planned for January 2027.
It has been proposed that high intrinsic activity at 5-HT1A postsynaptic receptors is necessary for maximal therapeutic benefits to come to prominence, and as a result, investigation has commenced in azapirones which act as 5-HT1A receptor full agonists such as alnespirone and eptapirone. Indeed, in preclinical studies, eptapirone produces robust antidepressant effects which surpass those of even high doses of imipramine and paroxetine.
Sources: en.wikipedia.org
The music of Brazil was formed mainly from the fusion of European, Native Indigenous, and African elements. Until the nineteenth century, Portugal was the gateway to most of the influences that built Brazilian music, although many of these elements were not of Portuguese origin, but generally European. The first was José Maurício Nunes Garcia, author of sacred pieces with an influence of Viennese classicism. The major contribution of the African element was the rhythmic diversity and some dances and instruments. Popular music since the late eighteenth century, samba was considered the most typical and on the UNESCO cultural heritage list. Samba-reggae, Axé, Maracatu, Frevo and Afoxê are four music traditions that have been popularized by their appearance in the annual Brazilian Carnivals. Capoeira is usually played with its own music referred to as capoeira music, which is usually considered to be a call-and-response type of folk music. Forró is a type of folk music prominent during the Festa Junina in northeastern Brazil. Jack A. Draper III, a professor of Portuguese at the University of Missouri, argues that Forró was used as a way to subdue feelings of nostalgia for a rural lifestyle. Choro is a popular musical instrumental style. Its origins are in 19th-century Rio de Janeiro. The style often has a fast and happy rhythm, characterized by subtle modulations and full of syncopation and counterpoint. lambada and Carimbó achieved success in Latin music, originating from Pará.
== Inventions == James Watt did not invent the steam engine, nor were his ideas on steam engine power inspired by a kettle lid pressured open by steam. Watt improved upon the already commercially successful Newcomen atmospheric engine (invented in 1712 by Thomas Newcomen) in the 1760s and 1770s, making certain improvements critical to its future usage; his new steam engine later gained huge fame as a result. Although the guillotine was named after the French physician Joseph-Ignace Guillotin, he neither invented nor was executed with this device. He died peacefully in his own bed in 1814. Rather, it was Guillotin's speech favoring beheadings over other forms of execution that led to the device being referred to as "La machine Guillotine" and later simply guillotine. Thomas Crapper did not invent the flush toilet. A forerunner of the modern toilet was invented by the Elizabethan courtier Sir John Harington in the 16th century, and in 1775 the Scottish mechanic Alexander Cumming developed and patented a design for a toilet with an S-trap and flushing mechanism. Crapper, however, did much to increase the popularity of the flush toilet and introduced several innovations in the late 19th century, holding nine patents, including one for the floating ballcock. Thomas Edison did not invent the light bulb.
== Further reading == Baena-Cagnani CE (2001). "Desloratadine activity in concurrent seasonal allergic rhinitis and asthma". Allergy. 56 Suppl 65: 21–7. doi:10.1111/j.1398-9995.2001.00001.x-i1. PMID 11243501. Devillier P, Roche N, Faisy C (2008). "Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review". Clinical Pharmacokinetics. 47 (4): 217–30. doi:10.2165/00003088-200847040-00001. PMID 18336052. Geha RS, Meltzer EO (April 2001). "Desloratadine: A new, nonsedating, oral antihistamine". The Journal of Allergy and Clinical Immunology. 107 (4): 751–62. doi:10.1067/mai.2001.114239. PMID 11295678. Henz BM (2001). "The pharmacologic profile of desloratadine: a review". Allergy. 56 Suppl 65: 7–13. doi:10.1034/j.1398-9995.2001.00101.x. PMID 11243504.
==== 2014 ==== The WWE Network launched on February 24, 2014. Every pay-per-view event from this point forward aired on both traditional PPV outlets and the WWE Network. However, beginning with NXT Arrival, several additional events began airing exclusively on the Network. These Network exclusives are noted as "Network exclusive". Beginning in 2021, some countries saw their version of the WWE Network merge under another streaming platform (e.g., in the United States, the WWE Network merged under Peacock in March 2021, which transferred to ESPN's streaming service in September 2025). The "Network exclusive" note from 2021 to 2025 also covers these other platforms.
Network analysis seeks to understand the relationships within biological networks such as metabolic or protein–protein interaction networks. Although biological networks can be constructed from a single type of molecule or entity (such as genes), network biology often attempts to integrate many different data types, such as proteins, small molecules, gene expression data, and others, which are all connected physically, functionally, or both. Systems biology involves the use of computer simulations of cellular subsystems (such as the networks of metabolites and enzymes that comprise metabolism, signal transduction pathways and gene regulatory networks) to both analyze and visualize the complex connections of these cellular processes. Artificial life or virtual evolution attempts to understand evolutionary processes via the computer simulation of simple (artificial) life forms.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.